Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...
Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...
Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...
Patricia F. Lalor, Ph.D.; 1 Jeff Faint, Ph.D.; 1 York Aarbodem, M.Sc.; 1 Stefan G. Hubscher, F.R.C.Path.; 1 David H. Adams, M.D., F.Med.Sci.1 Thus, the outcome of the ...
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan ...
This study presents an innovative approach that harnesses controlled inflammation to guide neutrophil-mediated drug delivery, effectively overcoming the limitations imposed by tumor heterogeneity. By ...
GATA2 deficiency commonly causes monocytopenia, and it can cause neutropenia (low neutrophils) or aplastic anemia (lack of blood cell production) as well. This condition can also progress to cause ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for ...
Since most patients are asymptomatic and lack relevant biomarkers, LVDD has not attracted significant attention from clinicians. The neutrophil-to-lymphocyte ratio (NLR) is a widely studied ...